StreetInsider.com News Articles

Form PRER14A Vivos Therapeutics, Inc.

Wed, 21 Oct 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20261021/27216651.html

Form 8-K Vivos Therapeutics, Inc. For: Oct 20

Wed, 21 Oct 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20261021/27212848.html

Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard

Wed, 21 Oct 2026 07:00:00 -0400

LITTLETON, Colo., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea (“OSA”) and other breathing and sleep-related health conditions, today announced receipt of a letter from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) on October 20, 2026 stating that the Company currently complies with Listing Rule 5550(b)(1), requiring the Company to maintain stockholders’ equity of at least $2.5 million.

The Company previously

Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard

Wed, 21 Oct 2026 07:00:00 -0400

The Company previously

Vivos Therapeutics acquires stake in SOD Sciences in stock-only deal

Mon, 19 Oct 2026 17:02:11 -0400

Vivos Therapeutics, Inc. (Nasdaq: VVOS) announced it has closed the acquisition of an 11% fully diluted equity interest in SOD Sciences, Inc. and a 50% undivided co-ownership interest in SOD Sciences' pseudohypoxia early-warning test, known as the "Primed Cell for Chronic Disease" test.

In exchange, Vivos issued 12,000 shares of newly created Series C Convertible Preferred Stock with an aggregate stated value of $12 million to SOD Sciences. No cash consideration was paid by either party. The preferred stock is convertible at a fixed price of $0.15 per share into up to 80,000,000 shares of common stock, subject to a 19.99%

Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel

Mon, 19 Oct 2026 17:01:00 -0400

LITTLETON, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos” or the “Company”) today announced that it has closed its acquisition of an 11% fully diluted equity interest in SOD Sciences, Inc. (“SOD Sciences” or “SOD”) and a 50% undivided co-ownership interest in SOD's pseudohypoxia early‑warning test, the "Primed Cell for Chronic Disease" test. In exchange, Vivos issued to SOD 12,000 shares of newly created Series C Convertible Preferred Stock with an aggregate stated value of $12 million. No cash consideration was paid by either party. Through the joint marketing arrangement to be negotiated

Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel

Mon, 19 Oct 2026 17:01:00 -0400

Form PRE 14A Vivos Therapeutics, Inc. For: Oct 19

Mon, 19 Oct 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20261019/27204617.html

Form 8-K Vivos Therapeutics, Inc. For: Oct 15

Mon, 19 Oct 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20261019/27204547.html

Vivos Therapeutics to acquire stake in SOD Sciences via stock deal

Thu, 15 Oct 2026 08:45:16 -0400

Vivos Therapeutics, Inc. (Nasdaq: VVOS) has agreed to acquire an 11% fully diluted equity interest in SOD Sciences, Inc. and a 50% undivided co-ownership interest in SOD's pseudohypoxia early-warning test, according to a company statement.

The transaction involves no cash consideration. Vivos will issue 12,000 shares of newly created Series C Convertible Preferred Stock with an aggregate stated value of $12 million. The preferred stock is convertible into common stock at a fixed price of $0.15 per share, representing up to 80 million shares, subject to a 19.99% exchange cap pending stockholder approval and a 4.99% beneficial ownership limitation.

Closing is subject

Form 8-K Vivos Therapeutics, Inc. For: Oct 14

Thu, 15 Oct 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20261015/27190443.html

Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test

Thu, 15 Oct 2026 08:45:00 -0400

Transaction Expected to Increase Stockholders’ Equity; Opens Potential Collaboration Opportunities From New Strategic Alliances

LITTLETON, Colo., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced that it has entered into a definitive Mutual Stock Purchase and Asset Exchange Agreement to acquire an 11% fully diluted equity interest in SOD Sciences, Inc. and a 50% undivided co-ownership interest

Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test

Thu, 15 Oct 2026 08:45:00 -0400

Transaction Expected to Increase Stockholders’ Equity; Opens Potential Collaboration Opportunities From New Strategic Alliances

Form 8-K Vivos Therapeutics, Inc. For: Sep 29

Thu, 01 Oct 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20261001/27130961.html

Vivos Therapeutics targets $3.6M in annual cost cuts, eyes revenue growth

Tue, 29 Sep 2026 08:46:43 -0400

Vivos Therapeutics, Inc. (Nasdaq: VVOS) announced a restructuring and cost reduction plan projected to save an estimated $3.6 million annually, with implementation beginning in Q4 2026, according to a company press release.

The cost reductions stem from staff reductions, vendor relationship changes, and renegotiated contracts. Parts of the plan were already in place as of the announcement, with additional reductions taking effect October 1, 2026.

The Littleton, Colo.-based medical device company also outlined several revenue growth initiatives. Referrals to its Las Vegas Sleep and Airway Medicine Centers rose approximately threefold from June through late September, with related revenue expected to appear in

Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives

Tue, 29 Sep 2026 08:45:00 -0400

Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line Revenue

LITTLETON, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other breathing and sleep disorders, today announced execution by management on a restructuring and cost reduction plan aimed at saving an estimated $3.6 million annually, beginning in Q4 2026. Parts of the plan have already

Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives

Tue, 29 Sep 2026 08:45:00 -0400

Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line Revenue

Form 4 Vivos Therapeutics, Inc. For: Sep 14 Filed by: SOKOLOW LEONARD J

Fri, 18 Sep 2026 20:20:00 -0400

si-local-file:///var/storage/secattach/20260918/27081553.html

Form 4 Vivos Therapeutics, Inc. For: Sep 14 Filed by: JOHNSON GREGG C

Fri, 18 Sep 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260918/27081551.html

Form 4 Vivos Therapeutics, Inc. For: Jun 30 Filed by: Huntsman Ronald Kirk

Fri, 18 Sep 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260918/27081243.html

Vivos Therapeutics cuts debt by exchanging shares with creditor

Tue, 08 Sep 2026 08:45:37 -0400

Vivos Therapeutics, Inc. (Nasdaq: VVOS) announced it entered into twelve exchange agreements with Streeterville Capital, LLC on August 31, 2026, converting $2,861,270 of outstanding principal from a secured promissory note into 11,445,080 shares of common stock at $0.25 per share.

The company also previously exchanged $3,250,000 of principal under the same note for 2,500 shares of Series B Non-Convertible Preferred Stock and 1,812,031 shares of common stock, as announced on August 4, 2026.

Following both transactions, the outstanding balance of the Streeterville note, inclusive of fees and original issue discount, stands at approximately $3.7 million as of August 31, 2026, down from

Vivos Therapeutics Announces Material Debt Reduction

Tue, 08 Sep 2026 08:45:00 -0400

Company Continues to Make Significant Progress to Enhance Stockholders' Equity and Satisfy Nasdaq Listing Requirements

LITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced that on August 31, 2026, Vivos entered into twelve exchange agreements with Streeterville Capital, LLC, exchanging $2,861,270 of outstanding principal under its secured promissory note (the "Streeterville Note") for 11,445,080 shares of common stock at an

Vivos Therapeutics Announces Material Debt Reduction

Tue, 08 Sep 2026 08:45:00 -0400

Company Continues to Make Significant Progress to Enhance Stockholders' Equity and Satisfy Nasdaq Listing Requirements

Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference

Tue, 01 Sep 2026 08:00:00 -0400

Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Company"), a leading medical technology and healthcare services company focused on the diagnosis and treatment of obstructive sleep apnea (OSA) and related breathing and sleep disorders, today announced that Founder and Chief Executive Officer R. Kirk Huntsman will present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference, taking place September 9 and 10, 2026, at The Westin New York Grand Central in New York City.

Mr. Huntsman is scheduled to present on Wednesday, September 9, 2026, at 8:45 a.m. Eastern Time,

Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference

Tue, 01 Sep 2026 08:00:00 -0400

Mr. Huntsman is scheduled to present on Wednesday, September 9, 2026, at 8:45 a.m. Eastern Time,